Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OMB health desk appointment

Executive Summary

Keith Fontenot has been recruited from the Congressional Budget Office to head the health desk at the Office of Management and Budget. At OMB he will join his former boss, Peter Orszag, OMB's new director. Fontenot previously served as a top aide for health care budgeting at CBO and is a 26-year veteran of budget analysis in health and human service areas. His new role puts him in a prominent position to monitor the purse strings of government activities, including entitlement programs run by CMS, research funding by the National Institutes of Health and drug regulation by FDA

You may also be interested in...



FDA Commissioner Update: Announcement Timing Provides Clues

White House says decision will be unveiled this week. The timing offers clues to who may have made the final cut.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel